Birthmark Removal in Vienna AT
Birthmarks are stains on your skin that appear at birth or shortly afterwards. Sometimes they are small and remain unnoticed, but sometimes they can be conspicuous and large. In the latter case you may feel uncomftable with your look and have a low self-esteem.
There are few kinds of bithmarks: Pigmented birthmarks also called congenital nevi or moles which may have some precancerous potential; Mongolian spots which are blue-green spots usually found in children and disappear as they grow older; and Coffee-cream spots which caused by to many pigment and usually pose only cosmetic problems. Macular stains, also called salmon patches, usually appear on babies and disappear later in life, except those found on the neck. Abnormal blood vessels create stains which are called Port wine stains. Those do not disappear during life and are especially concerning when appearing around the eyes. Hemangiomas are vascular tumors of many tiny blood vessels, which grow early in life around the head and neck. Many of them disappear after a few months but others may take years to disappear.
There are few methods by which a birthmark is removed. That depends largely on their size, type and location.
Laser therapy is one of the methods used, especially for superficial skin lesions. Laser energy targeted at a specific location causes the skin to fade and become lighter. In a case of port wine stain the laser makes it smaller and prevents from growing further. Laser treatments can be performed at any age, but sometimes several treatments are required.
Surgery is another method used for birthmarks, which cannot be removed by using laser. One example is hemangioma which is too large.
Laser treatment may take from several minutes to an hour, depending on the size of birthmarks. There is very little pain associated with the laser procedure. You may feel a mild burning sensation. Small children, or people sensitive to pain, may receive anesthetics. After the procedure has been completed, the skin is dark purple, and should improve after 7-10 days. Complete healing takes up to 6 weeks, during which you should avoid rubbing the place and exposing it to direct sun.
Every procedure has its risks. This one include pigmentation changes, resulting in areas of dark skin with bright patches. Such can be treated by additional laser treatments. Scar formation may also occur, where it can be treated by skin grafting. Other complications, such as bleeding or infection, are relatively rare.
More Vienna info...
Vienna Fast Food and Snacks
The traditional Viennese fast food is sausage. You can buy hot sausages and hot dogs at snack bars called "W?rstelstand" all over the town. The famous Wiener W?rstel is also known as the Frankfurter in Vienna, but most inhabitants prefer Burenwurst and K?sekrainer (sausage filled with cheese).
A relatively new addition to the local snack culture is D?ner Kebap, sandwiches of Turkish origin with roasted meat, salad and yogurt sauce. Places that sell kebap often sell take-away pizza too. Some conservatives are afraid that kebap will gain more popularity than sausages, and perhaps they are right.
Good kebaps can be bought at the Naschmarkt; the lower end of the Naschmarkt (furthest away from Karlsplatz or city centre) is cheaper than the upper end. Another good place to find snacks (especialy whilegoing out) is "Schwedenplatz".
-
Plastic Surgery News...
- An 8-year-old Jersey dairy cow is back at her Kansas farm thanks to a decade of research and an experimental surgery performed at Kansas State University's Veterinary Medical Teaching Hospital.The cow, named Wilhelmina Jolene by the veterinary students assigned to her case, sustained a breeding injury in December 2007 when the cruciate ligament in her right knee ruptured. Dr.
Context Gene expression profiling may be useful for prognostic and therapeutic strategies in breast carcinoma.
Objectives To demonstrate the value in integrating genomic information with clinical and pathological risk factors, to refine prognosis, and to improve therapeutic strategies for early stage breast cancer.
Design, Setting, and Patients Retrospective study of patients with early stage breast carcinoma who were candidates for adjuvant chemotherapy; 964 clinically annotated breast tumor samples (573 in the initial discovery set and 391 in the validation cohort) with corresponding microarray data were used. All patients were assigned relapse risk scores based on their respective clinicopathological features. Signatures representing oncogenic pathway activation and tumor biology/microenvironment status were applied to these samples to obtain patterns of deregulation that correspond with relapse risk scores to refine prognosis with the clinicopathological prognostic model alone. Predictors of chemotherapeutic response were also applied to further characterize clinically relevant heterogeneity in early stage breast cancer.
Main Outcome Measures Gene expression signatures and clinicopathological variables in early stage breast cancer to determine a refined estimation of relapse-free survival and sensitivity to chemotherapy.
Results In the initial data set of 573 patients, prognostically significant clusters representing patterns of oncogenic pathway activation and tumor biology/microenvironment states were identified within the low-risk (log-rank P = .004), intermediate-risk (log-rank P = .01), and high-risk (log-rank P = .003) model cohorts, representing clinically important genomic subphenotypes of breast cancer. As an example, in the low-risk cohort, of 6 prognostically significant clusters, patients in cluster 4 had an inferior relapse-free survival vs patients in cluster 1 (log-rank P = .004) and cluster 5 (log-rank P = .03). Median relapse-free survival for patients in cluster 4 was 16 months less than for patients in cluster 1 (95% CI, 7.5-24.5 months) and 19 months less than for patients in cluster 5 (95% CI, 10.5-27.5 months). Multivariate analyses confirmed the independent prognostic value of the genomic clusters (low risk, P = .05; high risk, P = .02). The reproducibility and validity of these patterns of pathway deregulation in predicting relapse risk was established using related but not identical clusters in the independent validation cohort. The prognostic clinicogenomic clusters also have unique sensitivity patterns to commonly used cytotoxic therapies.
Conclusions These results provide preliminary evidence that incorporation of gene expression signatures into clinical risk stratification can refine prognosis. Prospective studies are needed to determine the value of this approach for individualizing therapeutic strategies.